Adam R. Craig - Nov 9, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
President and CEO, Director
Signature
Adam R. Craig
Stock symbol
CTIC
Transactions as of
Nov 9, 2022
Transactions value $
-$1,250,961
Form type
4
Date filed
11/14/2022, 03:42 PM
Previous filing
Sep 14, 2022
Next filing
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $45.4K +54K +193.8% $0.84* 81.9K Nov 9, 2022 Direct
transaction CTIC common stock Sale -$277K -46.1K -56.32% $6.00 35.8K Nov 9, 2022 Direct F1
transaction CTIC common stock Sale -$45.7K -7.6K -21.24% $6.01 28.2K Nov 9, 2022 Direct F1
transaction CTIC common stock Sale -$1.8K -300 -1.07% $6.02 27.9K Nov 9, 2022 Direct F1
transaction CTIC common stock Options Exercise $158K +188K +675.87% $0.84* 216K Nov 10, 2022 Direct
transaction CTIC common stock Sale -$818K -136K -63.1% $6.00 79.8K Nov 10, 2022 Direct F1
transaction CTIC common stock Sale -$1.2K -200 -0.25% $6.01 79.6K Nov 10, 2022 Direct F1
transaction CTIC common stock Sale -$160K -26.7K -33.56% $6.01 52.9K Nov 10, 2022 Direct F1
transaction CTIC common stock Sale -$602 -100 -0.19% $6.02 52.8K Nov 10, 2022 Direct F1
transaction CTIC common stock Sale -$98.7K -16.4K -31.08% $6.02 36.4K Nov 10, 2022 Direct F1
transaction CTIC common stock Sale -$35K -5.8K -15.95% $6.03 30.6K Nov 10, 2022 Direct F1
transaction CTIC common stock Sale -$16.3K -2.7K -8.83% $6.04 27.9K Nov 10, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -54K -5.91% $0.00 859K Nov 9, 2022 Common Stock 54K $0.84 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -188K -21.91% $0.00 671K Nov 10, 2022 Common Stock 188K $0.84 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.